- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03825965
Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT
The Effect of Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following Total Knee Arthroplasty: A Multicenter, Randomized Pilot Trial
Each year, approximately 75,000 Canadians undergo knee replacement surgery, and up to 25% develop persistent post-surgical pain. Persistent post-surgical pain is associated with depression, anxiety, unemployment, and reduced quality of life. Chronic pain after surgery is often managed with opioid therapy, which typically provides only modest benefits and is associated with rare but serious adverse events, such as overdose and death. A number of studies have found that greater pain just before and after knee replacement surgery is associated with the development of chronic pain, suggesting that reducing peri-operative pain may help prevent persistent post-surgical pain.
Medicinal cannabis has begun to emerge as a potential therapy for pain reduction, and produces effects largely due to 2 active components: (1) cannabidiol (CBD), and (2) tetrahydrocannabinol (THC). Studies of CBD have shown analgesic, anti-inflammatory, and anti-anxiety properties, but without the psychoactive effects (feeling 'high') that THC produces. This study will assess the feasibility of a definitive trial to explore whether adding CBD dominant vs. placebo to usual care before and after surgery can reduce the rate of persistent post-surgical pain after total knee replacement. This study will randomize 40 patients to receive either CBD dominant or placebo, and follow them for six months to confirm our ability to recruit patients, adhere to protocol, and capture full outcome data for at least 85% of patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Anthony Adili, MD, P.Eng
- Phone Number: 36062 (905) 522-1155
- Email: adilia@mcmaster.ca
Study Contact Backup
- Name: Kim Madden, PhD
- Phone Number: (289) 237-7380
- Email: maddenk@mcmaster.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- Recruiting
- St. Joseph's Healthcare Hamilton
-
Contact:
- Anthony Adili, MD, P.Eng
- Phone Number: 36062 (905) 522-1155
- Email: adilia@mcmaster.ca
-
Toronto, Ontario, Canada, M5B 1W8
- Not yet recruiting
- St. Michael's Hospital
-
Contact:
- Amit Atrey, MD
- Phone Number: 1(416)864-5342
- Email: amit.atrey@unityhealth.to
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing TKA aged 18 or older
- Cognitive ability and English-language skills required to complete outcome measures
- Provision of informed consent
- Successful completion of the run-in period
Exclusion Criteria:
- Severe cardio-respiratory disease (For operationalizing: ASA 4/NYHA 4)
- Substance use disorder based on DSM-V criteria
- Allergy or intolerance to cannabis, cannabis derivatives, or other ingredients of the study drug
- Patients who are pregnant, planning to be pregnant, or breastfeeding
- Revision TKA
- Bilateral TKA
- Presenting for their pre-surgical consultation less than 4 weeks before surgery
- Patients with a chronic pain condition affecting the knee (other than osteoarthritis) (e.g.: patients with knee pain due to fibromyalgia or chronic pain syndrome will be excluded)
- Unwilling or unable to follow the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MPL-001 (CBD: THC 25:1)
125mg CBD/5 mg THC oil for oral use
|
25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
|
Placebo Comparator: Placebo
Visually identical placebo (medium chain triglyceride oil)
|
Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistent post-surgical pain (PPSP)
Time Frame: 6 months
|
Proportion of patients experiencing moderate to severe PPSP (average of pain over last week of ≥4 out of 10 on a numeric rating scale [NRS])
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid use
Time Frame: 6 months
|
Use of opioids (mean morphine equivalent dose [MED] change)
|
6 months
|
Peri-operative pain intensity
Time Frame: 24-48 hours, 2-weeks, 6-weeks, 3-months and 6-months
|
Peri-operative pain measured on an 11-point NRS
|
24-48 hours, 2-weeks, 6-weeks, 3-months and 6-months
|
Pain interference
Time Frame: 24-48 hours, 2-weeks, 6-weeks, 3-months and 6-months
|
Pain interference measured by the Brief Pain Inventory (BPI-SF)
|
24-48 hours, 2-weeks, 6-weeks, 3-months and 6-months
|
Physical function
Time Frame: 6 months
|
Physical component summary (PCS) score of the SF-12
|
6 months
|
Mental function
Time Frame: 6 months
|
Mental component summary (MCS) score of the SF-12
|
6 months
|
Return to function
Time Frame: 6 months
|
Return to 80% of pre-injury function (work, leisure, home activities)
|
6 months
|
Insomnia
Time Frame: 6 months
|
Insomnia symptoms on the Insomnia Severity Index (ISI)
|
6 months
|
Anxiety and depression
Time Frame: 6 months
|
Anxiety and depression on the Hospital Anxiety and Depression Scale (HADS)
|
6 months
|
Safety - Adverse events
Time Frame: 6 months
|
Serious and non-serious adverse events
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility - recruitment
Time Frame: 6 months
|
Ability to recruit 40 patients
|
6 months
|
Feasibility - retention
Time Frame: 6 months
|
Ability to follow 85% of patients
|
6 months
|
Feasibility - compliance
Time Frame: 6 months
|
Patient compliance with the study treatment (75% of patients comply with 75% of the study doses)
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Adili, MD, P.Eng, McMaster University
- Principal Investigator: Jason W Busse, DC, PhD, McMaster University
- Principal Investigator: Vahid Ashoorion, MD, PhD, McMaster University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cannabis TKA Pilot Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on MPL-001 (CBD: THC 25:1)
-
University Health Network, TorontoRecruitingChronic Pain | Cannabis | Opioid UseCanada
-
University of British ColumbiaVancouver General HospitalWithdrawn
-
Breath of Life International Pharma LtdCompleted
-
St. Joseph's Healthcare HamiltonMcMaster UniversityRecruitingDepression | Sleep Disorder | Insomnia | Depressive Disorder, Major | Insomnia ChronicCanada
-
Universita degli Studi della BasilicataSan Carlo Public Hospital, Potenza, ItalyCompleted
-
Santé CannabisTetra Bio-PharmaUnknown
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
-
Yale UniversityConnecticut Pharmaceutical SolutionsCompleted
-
Wayne State UniversityNot yet recruitingPTSD | Post Traumatic Stress DisorderUnited States
-
Kowa Research Institute, Inc.Completed